Dr. Wayne Danter, President and Founder of 123Genetix, will be attending the Canadian Organization for Rare Disorders’ (CORD) 2017 Fall Conference from November 6th to 7th at the Hyatt Regency in Toronto, Ontario.
A Moon Shot for Rare Disorders
The theme for this year’s conference is “A Moon Shot for Rare Disorders: Leave No one Behind.” Objectives of the conference are to create a shared understanding of the patient journey; to mobilize stakeholders around a common vision for Rare Disease Canada; and, to create a guiding framework to map current resources, define gaps, identify opportunities and challenges, and prioritize needs.
Research Empowering Technology
Dr. Danter will be on hand to discuss 123Genetix’s proprietary rare disease research empowering platform technology, DeepNEU – a highly novel deep learning computational platform that combines (1) extensive and publicly available rare diseases gene network data with (2) modified Neutrosophic Logic, and (3) features of deep ANNs and Support Vector Machines.
Interested parties wanting to meet with Dr. Danter during the conference should contact him by email at firstname.lastname@example.org.
CORD is Canada’s national network for organizations representing all those with rare disorders. CORD provides a strong common voice to advocate for health policy and a healthcare system that works for those with rare disorders. CORD works with governments, researchers, clinicians and industry to promote research, diagnosis, treatment and services for all rare disorders in Canada. For more information, visit the organization’s website at www.raredisorders.ca.
123Genetix is an innovative new social enterprise created to empower rare disease research. At 123Genetix we believe that rare should not mean forgotten. To empower rare disease research we have created a growing library of computational models of rare diseases. These models are easily customizable by the investigator and have a number of important applications. They are designed for hypothesis generation, research and experimental planning, grant writing and novel targeted therapy identification.
Join our growing base of rare disease advocates!